Introduction to Ocular Tuberculosis Therapeutics
Tuberculosis is a bacterial disease caused by the bacteria Mycobacterium tuberculosis that mainly affects the lungs. According to the World Health Organization, tuberculosis is one of the top ten leading causes of death in the world. About 10 million people were infected by tuberculosis around the world in 2017. In the same year, around 1.6 million deaths caused by tuberculosis were reported, out of which, 0.3 million deaths were associated with HIV.
However, the occurrence of tuberculosis is not limited to lungs. Ocular tuberculosis is a rare form of tuberculosis that infects various parts of an eye including the lid, cornea or the surrounding area. The therapeutics for treatment of ocular tuberculosis mainly include medication in the form of single and multi-drug doses.
Market Size and Forecast
In 2017, more than 9000 cases of people infected with tuberculosis were reported in the United States, which gives a rate of 2.8 cases per 100000 people, as suggested by CDC. This rate is 2.3% lower than the rate in 2016. Decreasing the rate further by improving the quality of therapeutics could control the spread of tuberculosis of all forms.
The ocular tuberculosis therapeutics market is anticipated to record a significant CAGR over the forecast period i.e. 2019-2027. The market is segmented by treatment and by end users, out of which, the treatment segment is further subdivided into first line treatment, second line treatment and combination therapy. On the basis of treatment, the combination therapy segment is anticipated to hold the largest share in the ocular TB therapeutics market on account of growing prevalence of multi-drug resistant tuberculosis. The various combinations of drugs, when given in correct dosage, prevent the incidence of ocular tuberculosis and cure the disease.
The first line drugs for ocular tuberculosis include Rifampicin, Isoniazid, Ethambutol and Pyrazinamide. These drugs are used at the initial stage of tuberculosis. The second line tuberculosis drugs comprise of Flouroquinolones, Aminoglycosides, Cycloserine, Polypeptides, p-Aminosalicylic acid and Thioamides. The market for these drugs is anticipated to reach a significant market size during the forecast period.
The growth of this market can be attributed to growing demand for improved therapeutics for the treatment of tuberculosis, including ocular tuberculosis. The global tuberculosis therapeutics market is anticipated to record a CAGR of around 5% during the forecast period. The increased funding in healthcare and clinical research by both private and public institutions and government organizations is a major factor leading to the growth of tuberculosis therapeutics market. DOWNLOAD SAMPLE REPORT HERE
Emerging Therapeutics for Multidrug Resistant TB Bacteria
Increased usage of antimicrobial drugs for treatment of tuberculosis has led to the evolution of multi-drug resistant varieties of TB bacteria. The continuously evolving bacteria creates a higher demand for improved therapeutics for ocular tuberculosis. W.H.O. (World Health Organization) estimated that in 2017, there were around 558000 cases of people with multi-drug resistant tuberculosis. Out of these, 82% cases were found to be resistant to rifampicin, which is the most effective first line drug. In order to treat this form of tuberculosis, new therapeutics are required, thereby driving the growth of ocular TB therapeutics market.
Increasing Research And Development Activities To Boost The Market Growth
The rising demand for ocular TB medication is anticipated to increase the research and development activities undertaken by various public and private institutions around the world. This can be attributed to the growing prevalence of tuberculosis among the population. TB is a highly contagious disease, and is extremely prevalent among HIV infected people. Increased incidence of HIV infection is another factor driving the growth of this market.
Rare Occurrence of Ocular Tuberculosis to Limit the Market Demand
Ocular TB, being a rare condition, is currently undergoing research and study. As a result, there is limited availability of drugs or other therapeutics for the treatment of tuberculosis of the eye. This is estimated to hinder the growth of ocular TB therapeutics market during the forecast period.
Our in-depth analysis of the ocular tuberculosis therapeutics market includes the following segments:
By End Users
On the basis of regional analysis, the ocular tuberculosis therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
Ocular TB therapeutics market in North America is estimated to hold the largest market share during the forecast period. This can be attributed to increasing developments in the healthcare industry and growing demand for better tuberculosis therapies in this region. The market in Asia-Pacific region is anticipated to grow at the highest rate during the forecast period on account of rising research activities and increased funding in the healthcare sector by government and private institutions. The high population in the region, mainly in countries such as China, India and Japan, in addition to the growing prevalence of communicable diseases including tuberculosis, are estimated to support the growth of the ocular tuberculosis therapeutics market.
The ocular TB therapeutics market is further classified on the basis of region as follows:
Top Featured Companies Dominating the Market
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization